Archives: news

Red Light Holland Corp has announced that it has received the first reports, produced by Shaman Pharma Corp. and CCrest Laboratories Inc. under Health Canada approval, evaluating the suitability of Red Light Holland’s natural psilocybin as a source of active pharmaceutical ingredients for scientific and potentially medical and therapeutic purposes.

With ketamine available as an off-label treatment for a number of mental health disorders, the present article discusses the need for regulatory oversight in the UK. Without adequate oversight, there may not be equitable access and availability of this treatment for those who need it.

As investors rush to profit from the psychedelic renaissance, their need for returns on their investments may jeopardize access to psychedelic-assisted therapies. This article discuses these ‘gate keeping’ activities and more as psychedelics edge toward medicalization.

The Drug Enforcement Agency (DEA) has again boosted the manufacturing of psychedelics such as psilocybin, psilocin, MDMA, LSD, and DMT in the United States with the release of its final production quotas for 2021.

The results of Compass Pathways recent COMP360 trial are explored in this article.

COVID-19 has exacerbated the the global mental health crisis we are experiencing. The present article explores the possibilities of using psychedelics to treat people with mental health disorders in a post-pandemic world. The article explores the past, present and future of psychedelic research.

This article discusses some of the findings from the COMP360 in which patients with treatment-resistant depression were administered psilocybin with psychological support. The trial was ran by Compass Pathways and is the largest trial to date with psilocybin.

This article breaks down a recent publication from Doss and colleagues (2021). In the study, it was found that psilocybin-assisted therapy can boost cognitive and neural flexibility.

Researchers at Monash University have been granted permission for the worlds first study using psilocybin to treat Generalized Anxiety Disorder. The research team have announced that their therapists will be offered psilocybin so that they can better understand their patients. This is the first trial to offer a classic psychedelic as a therapist training tool since 1974.